Type 2 Diabetes (T2D) Clinical Trials

Find Type 2 Diabetes (T2D) Clinical Trials Near You

Disentangling the Effect of Brain Insulin Resistance on Brain Health (BIR-BrainHealth)

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

People with diabetes are at increased risk of developing dementia, including Alzheimer's disease and vascular dementia. In addition, persons with diabetes have more pronounced age-related brain atrophy and cognitive difficulties compared to people without diabetes. The mechanisms behind the effects on the brain of diabetes are still unclear. New research suggests that the brains of some people with diabetes do not respond normally to insulin signals, a condition known as brain insulin resistance (BIR). To date, there have been no large clinical studies investigating BIR and its impact on brain health, but several smaller studies suggest that BIR may be a cause of cognitive decline and impaired brain health in people with diabetes. Another mechanism that may contribute to impaired brain health in people with diabetes is damage to the blood vessels in the brain. Damage to blood vessels is a well-known complication of diabetes, but how it affects the brain is not fully described. In this project, we will investigate the relationship between BIR and brain blood vessel dysfunction and its relationship to cognition and brain function. This is done by examining patients with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy controls. The participants will undergo MRI brain scans to assess the impact of BIR on the brain physiology and to evaluate brain blood vessel health. Participants will undergo comprehensive assessments of their cognitive abilities and thorough health examination.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 80
Healthy Volunteers: t
View:

• age 50-80 years

• Diagnosis of either type 1 diabetes or type 2 diabetes

• Diabetes duration of ≥10 years for individuals with type 1 diabetes and ≥5 years for individuals with type 2 diabetes

Locations
Other Locations
Denmark
Rigshospitalet
RECRUITING
Glostrup Municipality
Steno Diabetes Center Copenhagen
RECRUITING
Herlev
Germany
University of Ulm
RECRUITING
Ulm
Contact Information
Primary
Henrik BW Larsson, Professor
henrik.bo.wiberg.larsson@regionh.dk
+45 24824294
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2032-01
Participants
Target number of participants: 150
Treatments
Type 1 Diabetes
Individuals who have a type 1 diabetes diagnose and meet the inclusion and exclusion criteria.
Type 2 Diabetes
Individuals who have a type 2 diabetes diagnose and meet the inclusion and exclusion criteria.
Controls
Individuals who do not have a diabetes diagnose and meet the inclusion and exclusion criteria.
Sponsors
Collaborators: University of Ulm, Steno Diabetes Center Copenhagen
Leads: Henrik Bo Wiberg Larsson

This content was sourced from clinicaltrials.gov